News
Novo Nordisk teams with telehealth firms Hims, Ro to sell Wegovy at lower price
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth platforms. The strategy comes as rival Eli Lilly & Co. is working with telehealth firms to distribute lower-cost vials of its own obesity medication,
StockStory.org on MSN22h
Hims & Hers Health (HIMS) Shares Skyrocket, What You Need To KnowShares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 34.9% in the pre-market session after Novo Nordisk ...
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Hims & Hers Health partners with Novo Nordisk (NVO) to offer Wegovy, boosting weight-loss solutions. See why I remain ...
Fintel on MSN17h
TD Cowen Downgrades Hims & Hers Health (HIMS)Fintel reports that on April 29, 2025, TD Cowen downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from Buy to Hold.
Shares of Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) are surging on Tuesday. Shares soared after pharma giant ...
PEMBROKE PARK, Fla. – Drugmaker Novo Nordisk announced Tuesday that Wegovy will be available through telehealth providers.
In essence, Hims & Hers is embracing a "if you can't beat 'em, join 'em" approach that gives their customers more options.
Hims & Hers Health, Inc. (NYSE:HIMS) has emerged as a standout investment opportunity in the healthcare sector, showcasing remarkable growth and strategic potential. In this article, we will explore ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback